share_log

Mikra Commences Commercial Scale Production of Upgraded CELLF

Mikra Commences Commercial Scale Production of Upgraded CELLF

Mikra开始商业规模生产升级版CELLF
GlobeNewswire ·  2023/01/30 07:08

Marks major milestone toward imminent availability for sale to customers

标志着即将向客户销售的重要里程碑

TORONTO, Jan. 30, 2023 (GLOBE NEWSWIRE) -- Lifeist Wellness Inc. ("Lifeist" or the "Company") (TSXV: LFST) (FRANKFURT: M5B) (OTCMKTS: NXTTF), a health-tech company that leverages advancements in science and technology to build breakthrough companies that transform human wellness, today announced that its U.S. biosciences subsidiary Mikra Cellular Sciences Inc. ("Mikra") has begun commercial scale production of a new and improved version of CELLF.

多伦多,2023年1月30日(环球通讯社)--Lifeist Wellness Inc.(“Lifeist”或“公司”)(多伦多证券交易所股票代码:LFST)(法兰克福股票代码:M5B)(OTCMKTS:NXTTF)一家利用科技进步打造能够改变人类健康的突破性公司的健康科技公司今天宣布,其美国生物科学子公司Mikra细胞科学公司(“Mikra”)已开始商业规模生产一种新的改良版本的CELLF。

"Starting production of this new and improved version of CELLF is a major milestone following a lot of hard work behind the scenes by Mikra's team both on R&D and sourcing of new packaging and materials," said Meni Morim, CEO of Lifeist. "This advancement brings Mikra one step closer to shipping the new version to customers, and will help Mikra deliver on the promise of becoming a more meaningful contributor to Lifeist's financial performance in 2023."

Lifeist首席执行官梅尼·莫里姆表示:“在Mikra的团队在研发和采购新包装和材料方面进行了大量幕后艰苦工作后,开始生产这个新的改进版本是一个重要的里程碑。”这一进展使Mikra距离向客户交付新版本又近了一步,并将帮助Mikra兑现承诺,成为Lifeist 2023年财务业绩的更有意义的贡献者。

Added Faraaz Jamal, CEO of Mikra and COO of Lifeist, "When we first created CELLF, we prioritized efficacy, potency and safety, with the goal of establishing Mikra as an innovator in the market. This meant we made cognizant sacrifices with the first version of the formula in order to assure that we were making a safe product that really worked and lived up to our standards. With a successful launch under our belts, and a loyal consumer base, we are now positioned to build on the prior innovations while making improvements based on heartfelt customer feedback. The result of this R&D journey is beyond our expectations, and we look forward to introducing these upgrades to established and new customers."

Mikra首席执行官兼Lifeist首席运营官Faraaz Jamal补充道:“当我们第一次创建CELLF时,我们将疗效、效力和安全性放在首位,目标是将Mikra打造成市场上的创新者。这意味着我们在配方的第一个版本上做出了公认的牺牲,以确保我们制造的是真正有效并符合我们标准的安全产品。随着我们的成功推出,以及忠诚的消费者基础,我们现在已经准备好在之前的创新基础上再接再厉,同时根据客户真诚的反馈进行改进。这次研发之旅的结果超出了我们的预期,我们期待着将这些升级介绍给现有客户和新客户。

The key improvements in the upgraded version of CELLF include:

CELLF升级版的主要改进包括:

  • Significantly better taste
  • Brand new, one-handed accessible sachet design
  • Protective, environmentally friendly exterior packaging
  • Now dairy-free & vegan with no impact to delivery technology
  • 口感明显更好
  • 全新的单手无障碍香包设计
  • 环保型外包装
  • 现在不含乳制品和素食,对送货技术没有影响

"The new version of CELLF effectively addresses the feedback we received with version one, removing most major barriers in the sales funnel to purchase and increasing the probability of both customer retention and winback as we continue to grow and nurture our repeat customer community," said Jamal. "As we have recently seen, this incremental improvement has already opened up more distribution opportunities and we believe it will lead to higher gross margins and higher customer lifetime value."

贾马尔说:“新版本的CELLF有效地解决了我们在第一版中收到的反馈,消除了购买销售漏斗中的大多数主要障碍,并随着我们继续发展和培育我们的回头客群体,增加了留住客户和赢回客户的可能性。”正如我们最近看到的那样,这种渐进的改进已经打开了更多的分销机会,我们相信这将带来更高的毛利率和更高的客户终身价值。“

Concluded Jamal, "The evolution of CELLF was a necessary step to solidify it as Mikra's flagship product and set the internal mindset that the key to business longevity is the absence of complacence. This is only the first of many strategic, iterative improvements we will make to our product suite to ensure our delivery meets or exceeds customer expectations."

贾马尔总结道:“CELLF的发展是巩固其作为Mikra旗舰产品的必要步骤,并确立了企业长盛不衰的关键是不自满的内部思维。这只是我们将对我们的产品套件进行许多战略性迭代改进的第一步,以确保我们的交付达到或超过客户的预期。”

When production is complete, the new and improved formula will be available for purchase at wearemikra.com and will be the debut version of the product sold at GNC stores and .

当生产完成后,新的和改进的配方将在wearemikra.com上购买,并将成为在GNC商店和销售的产品的首个版本。

About Lifeist Wellness Inc.

关于Lifeist Wellness Inc.

Sitting at the forefront of the post-pandemic wellness revolution, Lifeist leverages advancements in science and technology to build breakthrough companies that transform human wellness. Portfolio business units include: CannMart, which operates a B2B wholesale distribution business facilitating recreational cannabis sales to Canadian provincial government control boards including for CannMart Labs, a BHO extraction facility producing high margin cannabis 2.0 products; Australian Vapes, one of Australia's largest online retailers of vaporizers and accessories; and Mikra, a biosciences and consumer wellness company developing and selling innovative therapies for cellular health.

坐在大流行后健康革命的前沿,Lifeist利用科学和技术的进步,建立了改变人类健康的突破性公司。业务组合包括:CannMart,经营B2B批发分销业务,为向加拿大省级政府控制委员会销售娱乐大麻提供便利,包括为CannMart Labs,一家生产高利润率大麻2.0产品的BHO提取工厂;Australian Vapes,澳大利亚最大的蒸发器及配件在线零售商之一;以及Mikra,一家生物科学和消费者健康公司,开发和销售针对细胞健康的创新疗法。

Information on Lifeist and its businesses can be accessed through the links below:

有关Lifeist及其业务的信息可通过以下链接访问:

lifeist.comcannmart.comroilty.coaustralianvaporizers.com.auwearemikra.com

Lifeist.comcannmart.comroilty.coaustralianvaporizers.com.auwearemikra.com

Contacts

联系人

Meni Morim, Lifeist Wellness Inc., CEO
Matt Chesler, CFA, FNK IR, Investor Relations
Ph: 647-362-0390
Email: ir@lifeist.com

Meni Morim,Lifeist Wellness Inc.首席执行官
马特·切斯勒,CFA,FNK IR,投资者关系
电话:647-362-0390
电子邮件:ir@life ist.com

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release or has in any way approved or disapproved of the contents of this press release.

多伦多证券交易所及其监管服务提供商(该术语在多伦多证券交易所的政策中定义)均不对本新闻稿的充分性或准确性承担责任,也不以任何方式批准或不批准本新闻稿的内容。

Forward Looking Information

前瞻性信息

This news release contains "forward-looking information" within the meaning of applicable securities laws. All statements contained herein that are not historical in nature contain forward-looking information. Forward-looking information can be identified by words or phrases such as "may", "expect", "likely", "should", "would", "plan", "anticipate", "intend", "potential", "proposed", "estimate", "believe" or the negative of these terms, or other similar words, expressions and grammatical variations thereof, or statements that certain events or conditions "may" or "will" happen.

本新闻稿包含适用证券法所指的“前瞻性信息”。本文中包含的所有非历史性陈述均含有前瞻性信息。前瞻性信息可以通过“可能”、“预期”、“可能”、“应该”、“将”、“计划”、“预期”、“打算”、“潜在”、“建议”、“估计”、“相信”或这些术语的否定或其他类似的词语、表达及其语法变体,或某些事件或条件“可能”或“将”发生的陈述来识别。

The forward-looking information contained herein, including, without limitation, statements related to the anticipated shipping to customers of the improved version of CELLF and the anticipated contribution to Lifeist's financial performance resulting from such sales during 2023, are made as of the date of this news release and is based on assumptions management believed to be reasonable at the time such statements were made, including, without limitation, expectations that and the improved version of CELLF will be available for purchase as anticipated and in a timely manner and gain market acceptance along with the expansion of the nutraceutical, its expectation that the market for nutraceutical products will remain strong and will continue to grow as currently anticipated, the nutraceutical market will continue to be a multi-billion dollar high-margin market, the introduction of new products, brands and distribution channels will generate additional awareness of Mikra's existing and future products and increase revenue. While we consider these assumptions to be reasonable based on information currently available to management, there is no assurance that such expectations will prove to be correct. By its nature, forward-looking information is subject to inherent risks and uncertainties that may be general or specific and which give rise to the possibility that expectations, forecasts, predictions, projections or conclusions will not prove to be accurate, that assumptions may not be correct and that objectives, strategic goals and priorities will not be achieved. A variety of factors, including known and unknown risks, many of which are beyond our control, could cause actual results to differ materially from the forward-looking information in this press release. Such factors include, without limitation: unanticipated production issues or delays with respect to the improved version of CELLF; the failure to make the improved version of CELLF available for distribution and sale as anticipated in 2023, the Company's inability to continue to develop Mikra's business as a whole, including its inability to increase distribution through retail and online channels, unanticipated changes to current regulations that would adversely impact Mikra's business, unforeseen developments that would delay Mikra's ability to develop and sell any nutraceutical products, the risk that the expected demand for nutraceutical products in general and those of Mikra in particular, including consumer uptake, does not develop as anticipated and risks relating to the Company's ability to execute its business strategy and the benefits realizable therefrom. Additional risk factors can also be found in the Company's current MD&A which has been filed under the Company's SEDAR profile at . Readers are cautioned not to put undue reliance on forward-looking information. The Company undertakes no obligation to update or revise any forward-looking information, whether as a result of new information, future events or otherwise, except as required by applicable law. Forward-looking statements contained in this news release are expressly qualified by this cautionary statement.

本文包含的前瞻性信息,包括但不限于与CELLF改进版的预期发货和2023年期间此类销售对Lifeist财务业绩的预期贡献有关的陈述,是截至本新闻稿发布之日作出的,基于做出此类陈述时被认为合理的管理假设,包括但不限于对CELLF和改进版CELLF将按预期和及时提供购买并随着营养食品的扩大而获得市场接受的预期。该公司预计,保健品市场将保持强劲,并将像目前预期的那样继续增长,保健品市场将继续是一个数十亿美元的高利润率市场,新产品、品牌和分销渠道的推出将增加对Mikra现有和未来产品的认识,并增加收入。虽然根据管理层目前掌握的信息,我们认为这些假设是合理的,但不能保证这样的预期将被证明是正确的。就其性质而言,前瞻性信息具有内在的风险和不确定性,这些风险和不确定性可能是一般性的,也可能是具体的,导致预期、预测或结论可能被证明不准确,假设可能不正确,目标、战略目标和优先事项将无法实现。各种因素,包括已知和未知的风险,其中许多是我们无法控制的,可能会导致实际结果与本新闻稿中的前瞻性信息大不相同。这些因素包括, 但不限于:与CELLF改进版本有关的意外生产问题或延误;未能按照预期在2023年提供CELLF的改进版本用于分销和销售,公司无法继续发展Mikra的整体业务,包括它无法通过零售和在线渠道增加分销,当前法规的意外变化将对Mikra的业务产生不利影响,意外的事态发展将推迟Mikra开发和销售任何保健产品的能力,对一般保健产品,特别是Mikra的预期需求,包括消费者的吸收,未按预期发展,以及与公司执行其业务战略的能力和由此可实现的利益相关的风险。其他风险因素也可以在公司目前的MD&A中找到,该报告已在公司的SEDAR简介中提交,网址为。告诫读者不要过度依赖前瞻性信息。除非适用法律要求,否则公司不承担因新信息、未来事件或其他原因而更新或修改任何前瞻性信息的义务。本新闻稿中包含的前瞻性陈述明确地受到本警示性声明的限制。

Source: Lifeist Wellness Inc.

来源:Lifeist Wellness Inc.


声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    抢沙发